Drugs / SC411
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT02604368 | Mar 2019 → Dec 2020 | sickle cell disease | Micelle BioPharma Inc | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SC411 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02604368 ↗ |
| Route | Oral | “SC411 is administered orally as a soft gel mini capsule.” NCT02604368 ↗ |